Stock CLXP.F CYBIN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Cybin Inc. Stock OTC Markets

Equities

CLXP.F

CA23256X1006

Biotechnology & Medical Research

End-of-day quote OTC Markets
Other stock markets
 06:00:00 2021-08-31 pm EDT 		5-day change 1st Jan Change
2.63 CAD -6.07% Intraday chart for Cybin Inc. +17.41% +76.51%
Jun. 11 Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development CI
May. 06 Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline CI

Financials

Sales 2024 * - Sales 2025 * - Capitalization 317M 231M
Net income 2024 * -74M -53.83M Net income 2025 * -70M -50.92M EV / Sales 2024 * -
Net cash position 2024 * 170M 124M Net cash position 2025 * 126M 91.52M EV / Sales 2025 * -
P/E ratio 2024 *
-1.76 x
P/E ratio 2025 *
-3.04 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.2%
More Fundamentals * Assessed data

Chart Cybin Inc.

Dynamic Chart

Latest news about Cybin Inc.

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development CI
Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline CI
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003 MT
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment MT
Cybin Inc. announced that it has received $150 million in funding from a group of investors CI
Sector Update: Health Care Stocks Softer Friday Afternoon MT
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder MT
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder CI
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial MT
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design CI
Sector Update: Health Care Stocks Ease Wednesday Afternoon MT
Cybin Says Depression Drug Granted Breakthrough Designation by FDA; Raises $150 Million in Private Placement; Shares Jump MT
Transcript : Cybin Inc. - Special Call
Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder CI
Cybin Inc. announced that it expects to receive $150 million in funding CI
More news

Latest transcript on Cybin Inc.

Logo Cybin Inc.
Cybin Inc. - Special Call
More transcripts

Analyst Recommendations on Cybin Inc.

HC Wainwright Adjusts Cybin Price Target to $5 From $10, Maintains Buy Rating MT
Oppenheimer Adjusts Cybin Price Target to $4 From $4.50, Maintains Outperform Rating MT
Canaccord Genuity Adjusts Price Target on Cybin to $5 From $6, Maintains Buy Rating MT
Stifel Nicolaus Adjusts Cybin's Price Target to $1.13 From $1.10, Maintains Speculative Buy Rating MT
Canaccord Genuity Trims Price Target on Cybin to $6 From $7, Maintains Buy Rating MT
More recommendations

Press releases Cybin Inc.

Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development BU
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024 BU
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase BU
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones AQ
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones  BU
More press releases

News in other languages on Cybin Inc.

Cybin berichtet über ein positives Treffen mit der FDA zum Ende der Phase 2 für CYB003 bei schweren depressiven Störungen und über die Planung eines Programms der Phase 3
Cybin annonce une réunion positive avec la FDA à la fin de la phase 2 pour le CYB003 dans le trouble dépressif majeur et la conception du programme de phase 3
Cybin reçoit la désignation de thérapie innovante de la FDA pour sa molécule psychédélique CYB003 et annonce des données de durabilité positives à quatre mois pour le traitement du trouble dépressif majeur
Annonce d’un placement privé sursouscrit de 150 millions USD
Cybin erhält von der FDA den Status eines Therapiedurchbruchs für sein neuartiges psychedelisches Molekül CYB003 und gibt positive Daten zur viermonatigen Dauerhaftigkeit bei schwerer depressiver Störung bekannt
More news

Managers and Directors - Cybin Inc.

Managers TitleAgeSince
Douglas Drysdale CEO
 Chief Executive Officer 54 20-07-31
Paul Glavine FOU
 Founder 35 16-10-12
Eric So FOU
 Founder 49 16-10-12
Members of the board TitleAgeSince
Eric So FOU
 Founder 49 16-10-12
Mark Lawson BRD
 Director/Board Member 52 20-11-04
Grant Froese BRD
 Director/Board Member 62 20-11-04
More insiders

Company Profile

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
Sector
Biotechnology & Medical Research
Calendar
2024-06-18 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.4176 CAD
Average target price
6.089 CAD
Spread / Average Target
+1,358.03%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.34% 124B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+15.06% 109B
BIONTECH SE Stock BioNTech SE
-6.39% 23.84B
ARGENX SE Stock argenx SE
+1.19% 22.42B
GENMAB A/S Stock Genmab A/S
-14.76% 17.5B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.64% 16.43B
BEIGENE, LTD. Stock BeiGene, Ltd.
-12.07% 16.61B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+1.05% 13.4B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+25.87% 11.47B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CYBN Stock
  4. CLXP.F Stock